- |||||||||| VesiGel (mitomycin intravesicular) / UroGen
P3 data, Journal, Monotherapy: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 (Pubmed Central) - Sep 11, 2023 Active, not recruiting --> Completed | Phase classification: P3b --> P3 | Trial completion date: May 2023 --> Feb 2023 Primary, non-surgical chemoablation with UGN-102 for the management of LG IR NMIBC offers a potential therapeutic alternative to immediate TURBT monotherapy and warrants further investigation.
- |||||||||| VesiGel (mitomycin intravesicular) / UroGen
Retrospective data, Review, Journal: A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer. (Pubmed Central) - Dec 16, 2022 Despite the lack of long-term outcomes, chemoablation appears to be a promising treatment option for well-selected NMIBC patients and can potentially help avoid unnecessary TURBT, specifically in some elderly patients with intermediate-risk NMIBC. Further well-designed studies with larger cohorts are necessary to address the differential tolerability and long-term anticancer efficacy of this resurging approach.
|